Orchestra BioMed Holdings, Inc. financial data

Symbol
OBIO on Nasdaq
Location
New Hope, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 420% % -14%
Quick Ratio 1.4% % 38%
Return On Equity -184% % -36%
Return On Assets -66% % 18%
Operating Margin -155% % 94%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58,520,901 shares 53%
Common Stock, Shares, Outstanding 57,032,963 shares 49%
Entity Public Float $63,400,000 USD -49%
Common Stock, Value, Issued $6,000 USD 50%
Weighted Average Number of Shares Outstanding, Basic 47,747,078 shares 30%
Weighted Average Number of Shares Outstanding, Diluted 47,747,078 shares 30%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $33,482,000 USD 1169%
Cost of Revenue $190,000 USD -6.9%
Research and Development Expense $58,185,000 USD 36%
Costs and Expenses $85,289,000 USD 27%
Operating Income (Loss) $51,807,000 USD 19%
Net Income (Loss) Attributable to Parent $52,701,000 USD 14%
Earnings Per Share, Basic -1.11 USD/shares 33%
Earnings Per Share, Diluted -1.11 USD/shares 33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $34,690,000 USD 56%
Marketable Securities, Current $71,822,000 USD 61%
Accounts Receivable, after Allowance for Credit Loss, Current $95,000 USD 3.3%
Inventory, Net $310,000 USD 79%
Assets, Current $107,911,000 USD 56%
Property, Plant and Equipment, Net $1,715,000 USD 24%
Operating Lease, Right-of-Use Asset $1,496,000 USD -29%
Assets $114,857,000 USD 51%
Accounts Payable, Current $6,095,000 USD 19%
Employee-related Liabilities, Current $4,160,000 USD 59%
Accrued Liabilities, Current $9,890,000 USD 63%
Liabilities, Current $16,736,000 USD 3.3%
Deferred Income Tax Liabilities, Net $393,000 USD -30%
Operating Lease, Liability, Noncurrent $936,000 USD -45%
Other Liabilities, Noncurrent $308,000 USD 670%
Liabilities $51,479,000 USD 19%
Accumulated Other Comprehensive Income (Loss), Net of Tax $60,000 USD 15%
Retained Earnings (Accumulated Deficit) $362,579,000 USD -17%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $53,570,000 USD 63%
Liabilities and Equity $114,857,000 USD 51%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $16,616,000 USD -27%
Net Cash Provided by (Used in) Financing Activities $296,000 USD
Net Cash Provided by (Used in) Investing Activities $12,999,000 USD 122%
Common Stock, Shares Authorized 340,000,000 shares 0%
Common Stock, Shares, Issued 57,032,963 shares 49%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,913,000 USD 46%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $34,690,000 USD 56%
Deferred Tax Assets, Valuation Allowance $108,271,000 USD 15%
Deferred Tax Assets, Gross $108,664,000 USD 15%
Operating Lease, Liability $1,687,000 USD -25%
Depreciation $327,000 USD 6.2%
Payments to Acquire Property, Plant, and Equipment $112,000 USD 1300%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $52,693,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid $1,868,000 USD -28%
Property, Plant and Equipment, Gross $3,346,000 USD 25%
Operating Lease, Liability, Current $751,000 USD 37%
Lessee, Operating Lease, Liability, to be Paid, Year Two $829,000 USD -5.8%
Lessee, Operating Lease, Liability, to be Paid, Year One $881,000 USD 18%
Operating Lease, Weighted Average Discount Rate, Percent 0.0992 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $181,000 USD -52%
Lessee, Operating Lease, Liability, to be Paid, Year Three $158,000 USD -81%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD -100%
Operating Lease, Payments $244,000 USD 7%
Additional Paid in Capital $416,083,000 USD 21%
Preferred Stock, Shares Outstanding 200,000 shares
Depreciation, Depletion and Amortization $83,000 USD 12%
Deferred Tax Assets, Net of Valuation Allowance $393,000 USD -30%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%